iTeos to Participate in Upcoming Investor Conferences

ITOS 11.26.2024

Full Press ReleaseSEC FilingsOur ITOS Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
  • 01.08.2025 - iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.06.2024 - 4 Statement of changes in beneficial ownership of securities

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:

7ThAnnual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, December 3, 2024Time: 9:35 AM ETLocation: Coral Gables, FL

Piper Sandler 36thAnnual Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Wednesday, December 4, 2024Time: 11:30 AM ETLocation: New York, NY

A live webcast of the conference presentation will be available on the Investors section of the company’s website atwww.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of InformationiTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

For further information, please contact:

Investor Contact:Carl MauchiTeos Therapeutics, Inc.carl.mauch@iteostherapeutics.com

Media Contact:media@iteostherapeutics.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com